Washington, May 8 - Representatives of anti-abortion organizations are scheduled to meet with White House officials on Friday as frustration mounts within the movement over what some see as an insufficiently aggressive federal agenda to curb abortion access.
The meeting follows public criticism from Marjorie Dannenfelser, president of Susan B. Anthony Pro-Life America, who told the Wall Street Journal that abortions in the United States have increased since the Supreme Court overturned Roe v. Wade in 2022 and added, "Trump is the problem." The remarks underscore strains between the president and portions of the anti-abortion coalition that were among his most steadfast supporters during his first presidential campaign.
Activists acknowledge the president's role in shifting the judicial landscape - crediting his Supreme Court appointments with contributing to the overturning of Roe - but several groups argue the administration has not pursued sufficiently forceful federal actions to reduce access to abortion. Their demands include tighter federal restrictions on the abortion pill mifepristone and more rigorous enforcement targeting online distributors of abortion medication.
The White House pushed back on those criticisms. White House spokeswoman Allison Schuster defended the administration's record, saying, "President Trump is the most pro-life and pro-family president in American history, and his Administration has announced a series of bold actions to safeguard life and uphold Americans' fundamental freedoms, including ending federal funding of abortion abroad." Susan B. Anthony Pro-Life America did not respond to a request for comment.
Data cited by the Guttmacher Institute show abortions have risen since the Supreme Court's 2022 ruling that removed the federal protection for abortion access. The institute estimates 1,126,000 abortions were provided by clinicians in 2025, a level it says is the highest since 2009. That increase is attributed largely to expanded use of abortion pills, which the institute reports now account for 65% of abortions in states where the procedure is legal.
The pressure campaign from lawmakers and advocacy groups has escalated in recent months. Republican lawmakers and anti-abortion organizations have urged the Food and Drug Administration to reexamine safety rules for mifepristone, a medication used in more than half of U.S. abortions. In March, Senate Republicans launched a probe into manufacturers of the abortion pill and called on the FDA to crack down on online sales of the drug.
The debate over medication access intensified following a string of court decisions concerning mail-order dispensing of mifepristone. This week, the U.S. Supreme Court temporarily restored access to the drug through telemedicine and mail delivery while litigation continues, leaving the regulatory and legal environment unsettled.
What this means
- Anti-abortion activists are pressing the White House for stronger federal measures focused on medication and online distribution.
- The administration defends its actions while legal and regulatory uncertainty persists over access to mifepristone.
- Data indicate a rise in clinician-provided abortions through 2025, with medication abortions constituting a growing share.